- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/02 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
Patent holdings for IPC class C07D 213/02
Total number of patents in this class: 195
10-year publication summary
|
8
|
8
|
14
|
8
|
11
|
6
|
8
|
16
|
17
|
5
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Boehringer Ingelheim International GmbH | 4493 |
8 |
| Bristol-myers Squibb Company | 4729 |
5 |
| Nocion Therapeutics, Inc. | 51 |
5 |
| Pillai Universal LLC | 18 |
5 |
| Aerpio Therapeutics, Inc. | 21 |
4 |
| Hoffmann-La Roche Inc. | 3783 |
3 |
| Genentech, Inc. | 4099 |
3 |
| Dana-Farber Cancer Institute, Inc. | 2662 |
3 |
| Universal Display Corporation | 2079 |
3 |
| Merck Sharp & Dohme LLC | 3735 |
3 |
| Wuhan Createrna Science and Technology Co.,Ltd. | 36 |
3 |
| The Procter & Gamble Company | 21861 |
2 |
| BASF SE | 21303 |
2 |
| Merck Sharp & Dohme Corp. | 2183 |
2 |
| Vertex Pharmaceuticals Incorporated | 1584 |
2 |
| University of Florida Research Foundation, Inc. | 4173 |
2 |
| Akebia Therapeutics, Inc. | 125 |
2 |
| Amira Pharmaceuticals, Inc. | 66 |
2 |
| Melinta Therapeutics, Inc. | 47 |
2 |
| RespiVert Ltd. | 79 |
2 |
| Other owners | 132 |